Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-08-16
1995-09-05
Warden, Jill
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530324, A61K 3800, C07K 500, C07K 700, C07K 1700
Patent
active
054479126
ABSTRACT:
Methods and compositions for inducing penile erections, sufficient for vaginal penetration, in a human male suffering from impotence are provided. Kits containing the compositions in containers for single dosage administration are provided.
Compositions for treating impotence that is of psychogenic or neurogenic origin contain a neuropeptide, vasoactive intestinal peptide and/or peptide N-terminal histidine C-terminal methioneamide and are formulated in a pharmaceutically acceptable carrier that has a pH of about 2 to about 4.5, preferably between about 2 and about 3.5, and most preferably about 3. Compositions for treating impotence of almost origin, including severe atherosclerosis, contain a neuropeptide, vasoactive intestinal peptide and/or peptide N-terminal histidine C-terminal methioneamide, and an .alpha.-adrenergic blocker, such as phentolamine or prazosin.
In practicing the methods, the composition is administered by intracavernosal injection accompanied by or followed by sexual stimulation.
REFERENCES:
patent: 3898329 (1975-08-01), Said et al.
patent: 4605641 (1986-08-01), Bolin et al.
patent: 4757133 (1988-06-01), Ito et al.
patent: 4853371 (1989-08-01), Coy et al.
patent: 4885164 (1989-12-01), Thurow
patent: 4935491 (1990-06-01), Folkers et al.
patent: 4935492 (1990-06-01), Lewicki et al.
patent: 4939224 (1990-03-01), Musso et al.
patent: 5147855 (1992-09-01), Gozes et al.
patent: 5217953 (1993-06-01), Gozes et al.
patent: 5236904 (1993-08-01), Gerstenberg et al.
Robberecht et al., "Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes", Eur. J. Biochem., 159 (1986) pp. 45-49.
Fournier et al., "Synthesis, Conformational Studies and Biological Activities of VIP and Related Fragments", Peptides, vol. 5 (1984), pp. 169-177.
Couvineau et al., "Structural Requirements for VIP Interaction With Specific Receptors in Human and Rat Intestinal Membranes: Effect of Nine Partial Sequences", Biochemical and Biophysical Research Communications, vol. 121, No. 2, Jun. 15, 1984, pp. 493-498.
Gerdin et al., "Structural Requirements for Microvascular Permeability-Increasing Ability of Peptides" i Biochimica et al Biophysical Acta, 757 (1983) pp. 366-370.
Weihe et al., "Distribution of vasoactive intestinal polypeptide-like immunoreactivity in the mammalian heart interrelation with neurotensin-and substances P-like immunoreactive nerves", Cell Tissue Research, (1984) 236:pp. 527-540.
Tischler et al., "Prodcution of `Ectopic` Vasoactive Intestinal Peptide-Like and Neurotensin-Like Immunoreactivity in Human Pheochromocytoma Cell Cultures", The Journal of Neuroscience, vol. 4, No. 5, pp. 1398-1404.
Endo et al., "Effects of Intraventricular Administration of Vasoactive Intestinal Peptide and Neurotensin heat Interrelation with neurotensin-and substances P-like immunoreactive nerves", Cell Tissue on Neurotensin on Salivary Seretion and Blood Pressure in the Rat Endocrinol. Japan, 1987, 34(6), pp. 927-935.
Schaaper et al. "Synthesis of Vasoactive Intestinal Peptide (VIP) via the Mixed Anhydride Method", Peptides, vol. 5, pp. 167-168.
Turner et al., "A Fragment of Vasoactive Intestinal Peptide, VIP(10-28), is an Antagonist of VIP in the Colon Carcinoma Cell Line, HT29", Peptides, vol. 7, (1986), pp. 849-854.
"Neoplasms", The Merck Manual of Diagnosis and Therapy, 11th Ed., (1966) pp. 1368-1371.
"Effects of Chronic Hyperprolactinemia on Sexual Arousal and Erectile Function in Male Rats", Neuroendocrinology, 42, (1986), pp. 368-375.
Ottesen, et al., "Vasoactive intestinal polypeptide (VIP) increases vaginal blood flow and inhibits uterine smooth muscle activity in women," Euro. Journal of Clinical Investigation 13:321-324 (1983).
Wagner, et al., "Intracavernosal injection of vascoactive intestinal polypeptide (VIP) does no induce erection in man per se," World Journal Urol., 5:171-172 (1987).
Kiely, et al., "Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents," British Journal of Urology, 64:191-194 (1989).
Brindley, "Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence," British Journal Psychiat., 143:332-337 (1983).
Willis, et al., "Vasoactive intestinal polypeptide (VIP) as a putative neurotransmitter in penile erection," Life Sciences, 33:383-391 (1983).
Ottesen, et al., "Penile erection: possible role for vasoactive intestinal polypeptide as a neurotransmitter," British Medical Journal, 288:9-11 (1984).
Adaikan, et al., "Is vasoactive intestinal polypeptide the principal transmitter involved in human penile erection?" The Journal of Urology, 135:638-640 (1986).
Itoh, et al., "Human preprovasoactive intestinal polypeptide contains a novel PHI-27-like peptide, PHM-27," Nature, 304:547-549 (1983).
Weiner, "Drugs that inhibit adrenergic nerves and block adrenergic receptors", in Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, MacMillan Publishing Co., New York, New York, 6th Ed., Chapter 9:176-210 (1980).
Blum et al., "Effect of local alpha-adrenergic blockade on human penile erection," J. Urol. 134(3):479-481 (1985), Abstr. from Dialog Info. Ser. File 155 AN=5677264.
Gerstenberg, et al., "Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure," J. Urol. 147:1277-1279 (1992).
Yianguo, et al., "Peptide histidine methionine (PHM) and the human male genitalia," Neuropeptides 6(2): 133-142 (1985).
Kirkeby, et al., "Effects of vasoactive intestinal peptide, peptide histidine methionine, and neuropeptide Y on intracavernous pressure in the rabbit," Urology 40(3):270-276 (1992).
Fahrenkrug, et al., "Vasoactive intestinal polypeptide and the reproductive system," Ann. N.Y. Acad. Sci. 527:393-404 (1988).
Polak and Bloom, "Localisation and measurement of VIP in the genitourinary system of man and animals," Peptides 5:225-230 (1984).
Bodner, et al., "Coding sequences for vasoactive intestinal peptide and PHM-27 peptide are located on two adjacent exons in the human genome," P.N.A.S. 82:3548-3551 (1985).
Willis et al., "Vasoactive intestinal polypeptide (VIP) as a possible neurotransmitter involved in penile erection," Chem. Abs. 96:4180p (1982).
Kirkeby et al., "Vasoactive intestinal polypeptide (VIP) and petide histidine methionine (PHM) in human penile corpus cavernosum tissue and circumflex veins: localization and in vitro effects," Euro. J. Clinic. Invest. 22:24-30 (1992).
Fahrenkrug and Pedersen, "Cosecretion of peptide histidine methionine (PHM) and vasoactive intestinal peptide (VIP) in patients with VIP-producing tumors," Peptides 7:717-721 (1986).
Palle et al., "Peptide histidine methionine and vasoactive intestinal peptide: Occurrence and relaxant effect in the human female reproductive tract," Biol. Repro. 41:1103-1111 (1989).
Coppard Nicholas J.
Fahrenkrug Jan
Gerstenberg Thomas
Ottesen Bent
Davenport A. M.
Senetek PLC
Warden Jill
LandOfFree
Erection-inducing methods and compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Erection-inducing methods and compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erection-inducing methods and compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-472793